{"id":11667,"date":"2021-01-26T12:09:42","date_gmt":"2021-01-26T06:39:42","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11667"},"modified":"2021-07-24T12:58:14","modified_gmt":"2021-07-24T07:28:14","slug":"pharma-happenings-for-merck-aurinia-wren-junshi-biosciences","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-aurinia-wren-junshi-biosciences","title":{"rendered":"Aurinia&#8217;s Lupkynis for Lupus; FDA Fast Track Designation for Toripalimab; Wren Therapeutics\u2019 Financing; Merck\u2019s Covid-19 Vaccine Program End"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a1183504e027\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a1183504e027\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-aurinia-wren-junshi-biosciences\/#Hot_on_the_heels_Aurinia_launches_its_drug_in_the_Lupus_market_after_GSK\" >Hot on the heels, Aurinia launches its drug in the Lupus market after GSK<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-aurinia-wren-junshi-biosciences\/#FDA_Fast_Track_Designation_to_Toripalimab_for_Mucosal_Melanoma\" >FDA Fast Track Designation to Toripalimab for Mucosal Melanoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-aurinia-wren-junshi-biosciences\/#Wren_Therapeutics_Announces_Financing_of_124_Million\" >Wren Therapeutics Announces Financing of \u00a312.4 Million&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-aurinia-wren-junshi-biosciences\/#Merck_Makes_a_Quick_Exit_in_the_COVID-19_Vaccine_Development_Fight\" >Merck Makes a Quick Exit in the COVID-19 Vaccine Development Fight&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Hot_on_the_heels_Aurinia_launches_its_drug_in_the_Lupus_market_after_GSK\"><\/span><strong>Hot on the heels, Aurinia launches its drug in the Lupus market after GSK<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Aurinia Pharmaceuticals<\/strong> has recently got the USFDA approval for its <strong>Lupkynis <\/strong>(voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/lupus-nephritis-market-insight-epidemiology-and-market-forecast?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">Lupus nephritis<\/a><\/strong> (LN). Lupkynis is the first oral therapy to receive FDA nod for Lupus nephritis, a condition that causes inflammation of kidneys. It is one of the most common and serious complications of the autoimmune disease <a href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-lupus-erythematosus-market-insight-epidemiology-and-market-forecast?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">systemic lupus erythematosus<\/a> (SLE).&nbsp;<\/p>\n\n\n\n<p>Lupus has been a challenging condition to treat for decades with only a limited number of therapeutic options. However, Aurinia is not the only player offering the cure. A month ago, <strong>GlaxoSmithKline <\/strong>earned the approval for its <strong>Benlysta<\/strong>, intravenous and subcutaneous option for Lupus, and became the first-ever therapy to get an approval for the indication.&nbsp;<\/p>\n\n\n\n<p>Although GSK has had an upper hand at the early launch of the drug, Aurinia has reported a significantly improved renal response rate of 40.8% versus 22.5% in the control arm while Benlysta\u2019s difference with control was smaller (43% vs 32%). Furthermore, the company does not shy away from saying that its drug works rapidly and its oral RoA is another added benefit that makes it stand tall in the Lupus nephritis market.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_Fast_Track_Designation_to_Toripalimab_for_Mucosal_Melanoma\"><\/span><strong>FDA Fast Track Designation to Toripalimab for Mucosal Melanoma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The USFDA granted Fast Track Designation to <strong>Junshi Biosciences<\/strong>\u2019 <strong>Toripalimab <\/strong>for the first-line treatment of mucosal melanoma. Toripalimab is the first domestic anti-PD-1 monoclonal antibody to get commercial approval in China.&nbsp;<\/p>\n\n\n\n<p>The regulatory agency has also approved the Investigational New Drug (IND) application for a global Phase III trial of Toripalimab in combination with Axitinib versus Pembrolizumab for the first-line treatment of patients with advanced mucosal <a href=\"https:\/\/www.delveinsight.com\/report-store\/melanoma-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">melanoma<\/a> (Combination Clinical Trial). The trial investigated more than fifteen indications sponsored by over thirty pharmaceutical companies conducted globally, including in China and the United States.&nbsp;<\/p>\n\n\n\n<p>In 2018, Toripalimab had already obtained conditional approval from the National Medical Products Administration (the \u201cNMPA\u201d) for the second-line treatment of unresectable or <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-melanoma-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">metastatic melanoma<\/a>. Further, it was included in the Guidelines of Chinese Society of Clinical Oncology (CSCO) for the Diagnosis and Treatment of Melanoma in 2019 and 2020 respectively. It also has received two supplemental New Drug Applications (NDAs) for the third-line treatment of recurrent\/metastatic nasopharyngeal carcinoma and the second-line treatment of metastatic urothelial carcinoma were accepted by the NMPA in April and May 2020, respectively.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wren_Therapeutics_Announces_Financing_of_124_Million\"><\/span><strong>Wren Therapeutics Announces Financing of \u00a312.4 Million&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Wren Therapeutics has announced the closing of a \u00a312.4 million (c. $17.0 million) financing raising the total capital to approximately \u00a333 million (c. $45 million). The financing was led by existing shareholder The Baupost Group, along with the participation from existing investors including LifeForce Capital and new investors including Schooner Capital and Industry Ventures.<\/p>\n\n\n\n<p>The company plans to use the proceeds to accelerate two of its leading small-molecule programs towards the clinical development for the potential treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">Alzheimer\u2019s disease<\/a> and various synucleinopathies including <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">Parkinson\u2019s disease<\/a>.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Merck_Makes_a_Quick_Exit_in_the_COVID-19_Vaccine_Development_Fight\"><\/span><strong>Merck Makes a Quick Exit in the COVID-19 Vaccine Development Fight&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The pharma goliath, Merck has decided to discontinue the development of its two experimental Covid-19 vaccines after the results from early trial gave some lacklustre results. Merck has taken a different approach from its rivals namely Pfizer, Moderna and Johnson &amp; Johnson who were also in the domain developing vaccines against <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">COVID-19<\/a>.&nbsp;<\/p>\n\n\n\n<p>Merck had undertaken two programs, <strong>V590<\/strong>, which is based on the borrowed technology from Merck\u2019s Ebola inoculation, whereas the second one, <strong>V591<\/strong>, is based on a measles vaccine used in Europe. However, both failed to cut the mustard this time and proved to be a blot in the company\u2019s long history of successful vaccine development.&nbsp;<\/p>\n\n\n\n<p>Merck was a late-entrant in the development of the<a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\"> COVID-19 vaccine<\/a>. The company had finished the recruitment of the first participants for early-stage safety studies at the time when its rivals were gearing up for presenting and demonstrating the efficacy of their candidates in late-stage trials. And the weak results took everyone by surprise. However, early or say quick fails are not as bad as the failure in the end-stage trials as they help the company to recover sooner from the grief and loss.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hot on the heels, Aurinia launches its drug in the Lupus market after GSK Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active Lupus nephritis (LN). Lupkynis is the first oral therapy to receive FDA nod for Lupus [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":11669,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[72,10830,15648,6248,394,1945,3422,460,721],"industry":[17225],"therapeutic_areas":[17231],"class_list":["post-11667","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimers-disease","tag-covid-19","tag-covid-19-vaccines","tag-lupus-nephritis","tag-melanoma","tag-merck-co","tag-parkinsons-disease-therapeutic-market","tag-pfizer","tag-systemic-lupus-erythematosus","industry-pharmaceutical","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Aurinia&#039;s Lupkynis for Lupus; Toripalimab; Merck\u2019s Covid-19 Vaccines fail<\/title>\n<meta name=\"description\" content=\"Aurinia&#039;s Lupkynis for Lupus; FDA Fast Track Designation for Toripalimab; Merck\u2019s Covid-19 Vaccine Program End Program\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-aurinia-wren-junshi-biosciences\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aurinia&#039;s Lupkynis for Lupus; Toripalimab; Merck\u2019s Covid-19 Vaccines fail\" \/>\n<meta property=\"og:description\" content=\"Aurinia&#039;s Lupkynis for Lupus; FDA Fast Track Designation for Toripalimab; Merck\u2019s Covid-19 Vaccine Program End Program\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-aurinia-wren-junshi-biosciences\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-26T06:39:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/25190615\/Aurinias-Lupkynis-for-Lupus-Toripalimab-Merck%E2%80%99s-Covid-19-Vaccines-fail.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Aurinia's Lupkynis for Lupus; Toripalimab; Merck\u2019s Covid-19 Vaccines fail","description":"Aurinia's Lupkynis for Lupus; FDA Fast Track Designation for Toripalimab; Merck\u2019s Covid-19 Vaccine Program End Program","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-aurinia-wren-junshi-biosciences","og_locale":"en_US","og_type":"article","og_title":"Aurinia's Lupkynis for Lupus; Toripalimab; Merck\u2019s Covid-19 Vaccines fail","og_description":"Aurinia's Lupkynis for Lupus; FDA Fast Track Designation for Toripalimab; Merck\u2019s Covid-19 Vaccine Program End Program","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-aurinia-wren-junshi-biosciences","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-01-26T06:39:42+00:00","article_modified_time":"2021-07-24T07:28:14+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/25190615\/Aurinias-Lupkynis-for-Lupus-Toripalimab-Merck%E2%80%99s-Covid-19-Vaccines-fail.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-aurinia-wren-junshi-biosciences","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-aurinia-wren-junshi-biosciences","name":"Aurinia's Lupkynis for Lupus; Toripalimab; Merck\u2019s Covid-19 Vaccines fail","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-aurinia-wren-junshi-biosciences#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-aurinia-wren-junshi-biosciences#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/25190615\/Aurinias-Lupkynis-for-Lupus-Toripalimab-Merck%E2%80%99s-Covid-19-Vaccines-fail.jpg","datePublished":"2021-01-26T06:39:42+00:00","dateModified":"2021-07-24T07:28:14+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Aurinia's Lupkynis for Lupus; FDA Fast Track Designation for Toripalimab; Merck\u2019s Covid-19 Vaccine Program End Program","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-aurinia-wren-junshi-biosciences"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-aurinia-wren-junshi-biosciences#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/25190615\/Aurinias-Lupkynis-for-Lupus-Toripalimab-Merck%E2%80%99s-Covid-19-Vaccines-fail.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/25190615\/Aurinias-Lupkynis-for-Lupus-Toripalimab-Merck%E2%80%99s-Covid-19-Vaccines-fail.jpg","width":772,"height":482,"caption":"Aurinia's Lupkynis for Lupus; Toripalimab; Merck\u2019s Covid-19 Vaccines fail"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/25190615\/Aurinias-Lupkynis-for-Lupus-Toripalimab-Merck%E2%80%99s-Covid-19-Vaccines-fail-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID-19<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Covid-19 vaccines<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lupus nephritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">melanoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck &amp; Co<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease therapeutic market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">COVID-19<\/span>","<span class=\"advgb-post-tax-term\">Covid-19 vaccines<\/span>","<span class=\"advgb-post-tax-term\">Lupus nephritis<\/span>","<span class=\"advgb-post-tax-term\">melanoma<\/span>","<span class=\"advgb-post-tax-term\">Merck &amp; Co<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease therapeutic market<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 26, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 26, 2021 12:09 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"Aurinia's Lupkynis for Lupus; Toripalimab; Merck\u2019s Covid-19 Vaccines fail","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11667"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11667\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11669"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11667"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11667"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}